- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.3: 7 residues within 4Å:- Chain A: N.58
- Chain B: G.16, S.17
- Chain G: Y.102, G.103
- Chain H: Y.49, Y.50
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.11: 6 residues within 4Å:- Chain C: N.58
- Chain D: S.17
- Chain I: Y.102, G.103
- Chain J: Y.49, Y.50
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.19: 5 residues within 4Å:- Chain E: N.58
- Chain F: S.17
- Chain K: Y.102, G.103
- Chain L: Y.49
1 PLIP interactions:1 interactions with chain K- Hydrogen bonds: K:G.103
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.5: 13 residues within 4Å:- Chain A: S.179, E.181, P.182, V.224, L.231, N.232, N.346, G.348, Q.408, C.413, V.414, S.415
- Ligands: NAG-NAG.1
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:V.414, A:R.274, A:Q.408, A:Q.408
NAG-NAG-BMA-MAN-MAN.13: 13 residues within 4Å:- Chain C: S.179, E.181, P.182, V.224, L.231, N.232, N.346, G.348, Q.408, C.413, V.414, S.415
- Ligands: NAG-NAG.9
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:G.348, C:V.414, C:Q.408, C:Q.408
NAG-NAG-BMA-MAN-MAN.21: 13 residues within 4Å:- Chain E: S.179, E.181, P.182, V.224, L.231, N.232, N.346, G.348, Q.408, C.413, V.414, S.415
- Ligands: NAG-NAG.17
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:G.348, E:V.414, E:Q.408, E:Q.408
- 21 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.25: 1 residues within 4Å:- Chain A: N.204
Ligand excluded by PLIPNAG.26: 5 residues within 4Å:- Chain A: S.357, G.358, N.361
- Ligands: NAG-NAG.4, NAG-NAG.4
Ligand excluded by PLIPNAG.27: 6 residues within 4Å:- Chain A: Q.263, N.265, N.301, V.302, S.303, R.412
Ligand excluded by PLIPNAG.28: 3 residues within 4Å:- Chain A: N.271, I.292, V.410
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain A: R.162, N.167
- Chain C: R.278
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain A: N.246, T.248, N.249
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain A: N.103, R.113
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain C: N.204
Ligand excluded by PLIPNAG.33: 5 residues within 4Å:- Chain C: S.357, G.358, N.361
- Ligands: NAG-NAG.12, NAG-NAG.12
Ligand excluded by PLIPNAG.34: 7 residues within 4Å:- Chain C: Q.263, N.265, N.301, V.302, S.303, R.412
- Ligands: NAG-NAG.15
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain C: N.271, I.292, V.410
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain C: R.162, N.167
- Chain E: R.278
Ligand excluded by PLIPNAG.37: 3 residues within 4Å:- Chain C: N.246, T.248, N.249
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain C: N.103, R.113, G.114
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain E: N.204
Ligand excluded by PLIPNAG.40: 5 residues within 4Å:- Chain E: S.357, G.358, N.361
- Ligands: NAG-NAG.20, NAG-NAG.20
Ligand excluded by PLIPNAG.41: 6 residues within 4Å:- Chain E: Q.263, N.265, N.301, V.302, S.303, R.412
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain E: N.271, I.292, V.410
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain A: R.278
- Chain E: R.162, N.167
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain E: N.246, T.248, N.249
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain E: N.103, R.113
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Banach, B.B. et al., Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site. Nat Commun (2023)
- Release Date
- 2023-09-27
- Peptides
- Envelope glycoprotein gp120: ACE
Envelope glycoprotein gp41: BDF
VRC34.01-MM28 FAB variable heavy chain: GIK
VRC34.01-MM28 FAB variable light chain: HJL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
EB
BD
DF
FG
GI
IK
KH
HJ
JL
L
SMTL ID : 8euw.1
Cryo-EM structure of HIV-1 BG505 DS-SOSIP ENV trimer bound to VRC34.01-MM28 FAB
Envelope glycoprotein gp120
Toggle Identical (ACE)Envelope glycoprotein gp41
Toggle Identical (BDF)VRC34.01-MM28 FAB variable heavy chain
Toggle Identical (GIK)VRC34.01-MM28 FAB variable light chain
Toggle Identical (HJL)Related Entries With Identical Sequence
4tvp.1 | 4zmj.1 | 5aco.1 | 5c7k.1 | 5cez.2 | 5cjx.1 | 5fyl.1 | 5i8c.1 | 5i8h.1 | 5i8h.2 | 5t3x.1 | 5t3z.1 | 5thr.1 | 5u7m.1 | 5u7o.1 | 5utf.1 | 5uty.1 | 5v7j.1 | 5v8l.1 | 5v8m.1 | 5viy.1 | 5vj6.1 | 5w6d.1 | 6cm3.1 | 6crq.1 | 6de7.1 | 6did.1 | 6me1.1 | 6me1.2 | 6mn7.1 more...less...6mtj.1 | 6mtn.1 | 6mu6.1 | 6mu7.1 | 6mu8.1 | 6nf2.1 | 6nm6.1 | 6nnf.1 | 6nnj.1 | 6opa.1 | 6osy.1 | 6ot1.1 | 6oz4.1 | 6ozc.1 | 6pw6.1 | 6u0l.1 | 6u0n.1 | 6udj.1 | 6vi0.1 | 6vn0.1 | 6w03.1 | 6x96.1 | 6x97.1 | 6x98.1 | 6x9r.1 | 6x9r.2 | 6x9r.3 | 6x9s.1 | 6x9s.2 | 6x9s.3 | 6x9t.1 | 6x9t.2 | 6x9t.3 | 6x9u.1 | 6x9u.2 | 6x9u.3 | 6x9v.1 | 6x9v.2 | 6x9v.3 | 6xrt.1 | 7kde.1 | 7lo6.1 | 7lok.1 | 7lpn.1 | 7mxe.1 | 7pc2.1 | 7rai.1 | 7tfn.1 | 7tfo.1 | 7txd.1 | 7ucf.1 | 7uoj.1 | 8dp1.1 | 8dto.1 | 8e1p.1 | 8euu.1 | 8euv.1 | 8fis.1 | 8fk5.1 | 8fl1.1 | 8flw.1 | 8fyj.1 | 8g85.1 | 8g9w.1 | 8g9x.1 | 8g9y.1 | 8gas.1 | 8jtd.1 | 8jtm.1 | 8sal.1 | 8san.1 | 8saq.1 | 8sat.1 | 8sav.1 | 8sw3.1 | 8sw4.1 | 8tjr.1 | 8tjs.1 | 8tkc.1 | 8tl2.1 | 8tl3.1 | 8tl4.1 | 8tl5.1 | 8tng.1 | 8tnh.1 | 8tni.1 | 8tnu.1 | 8to7.1 | 8top.1 | 8tq1.1 | 8ttw.1